Page last updated: 2024-09-05

sb 203580 and c.i. 42510

sb 203580 has been researched along with c.i. 42510 in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(c.i. 42510)
Trials
(c.i. 42510)
Recent Studies (post-2010) (c.i. 42510)
3,48941,1374,9601901,366

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
He, ZY; Luo, XG; Shang, H; Wang, XH; Xie, X1

Other Studies

1 other study(ies) available for sb 203580 and c.i. 42510

ArticleYear
Inhibiting purinergic P2X7 receptors with the antagonist brilliant blue G is neuroprotective in an intranigral lipopolysaccharide animal model of Parkinson's disease.
    Molecular medicine reports, 2017, Volume: 15, Issue:2

    Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Imidazoles; Immunohistochemistry; Lipopolysaccharides; Male; Microscopy, Fluorescence; p38 Mitogen-Activated Protein Kinases; Parkinson Disease; Phosphorylation; Protective Agents; Purinergic P2X Receptor Antagonists; Pyridines; Rats; Rats, Sprague-Dawley; Rosaniline Dyes

2017